# Signet Therapeutics Gets China Life Funding for Series A

> Signet Therapeutics secures China Life lead investment for Series A extension.
- Title: Signet Therapeutics Gets China Life Funding for Series A
- Summary: Signet Therapeutics secures China Life lead investment for Series A extension. Signet Therapeutics closed a Series A extension with China Life Equity…
- Keywords: signet therapeutics, china life equity investment, series a extension, oncology pipeline, heart disease, kidney disease, ai organoid drug discovery, Dealroom
- Source: Dealroom — https://dealroom.co/news/169425-signet-therapeutics-lands-lead-backing-from-china-life-for-series-a-exte
- Published: 2026-11-04T02:17:33+00:00
- Read time: 1 min
- Topics: signet therapeutics, china life equity investment, series a extension, oncology pipeline, heart disease, kidney disease, ai organoid drug discovery, startups, business
## Series A Extension Closed
Signet Therapeutics closed first tranche of Series A extension worth several hundred million yuan led by China Life Equity Investment.
## AI Organoid Drug Development
Signet builds organoid disease models matching patients' genomic traits and uses AI to screen drug candidates for efficiency.
## Key Programs in Progress
SIGX1094 targets diffuse gastric cancer as first FAK/SRC dual-target inhibitor; SIGX2649 is a pan-TEAD inhibitor advancing in pipeline.
## Key takeaway

Signet Therapeutics closed a Series A extension with China Life Equity Investment to advance its oncology pipeline and heart/kidney disease programs.